SCHEMBL16611302

SCHEMBL16611302

COCC(=O)N1CCN(c2ccc(-c3nn(-c4c(F)cccc4F)c4cc[nH]c(=O)c34)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
ALDH1A1 P00352 5/20 0.41
CYP3A4 P08684 5/20 0.41
MAPK1 P28482 4/20 0.41
USP2 O75604 3/20 0.41
CYP2D6 P10635 2/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 2/20 0.40
NAMPT P43490 1/20 0.39
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611486 0.91 AKR1C3 (0.38) ROCK2ROCK1ALDH1A1MAPK1MAPT
SCHEMBL16610679 0.88 GFER (0.37) ALDH1A1CYP3A4MAPK1USP2MAPT
SCHEMBL18052632 0.82 PTGER1 (0.33)
SCHEMBL16611949 0.81 ZAP70 (0.41) ROCK1ALDH1A1MAPK1USP2HPGD
SCHEMBL16726713 0.81 KHK (0.37) ALDH1A1CYP3A4MAPK1USP2TP53
SCHEMBL16611480 0.81 SMN1; SMN2 (0.38) ALDH1A1MAPK1USP2MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL16611399 0.80 ZAP70 (0.41) ROCK1ALDH1A1MAPK1USP2HPGD
SCHEMBL16611251 0.79 EED (0.39) ROCK1ALDH1A1TP53MAPTPOLB
SCHEMBL16623574 0.78 AKR1C3 (0.32)
SCHEMBL16611853 0.78 MAPK1 (0.42) ALDH1A1MAPK1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ROCK2 580/4885ROCK1 479/4885ALDH1A1 3511/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ROCK2 580/4885ROCK1 479/4885ALDH1A1 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.